Mela Sciences Cites Binding Study Protocol Pact As Key To FDA Reversal On MelaFind PMA

A rare binding study protocol agreement with FDA was a crucial factor in Mela Sciences’ successful campaign to reverse an initial “not approvable” determination for the firm’s melanoma detection device, according to CEO Joseph Gulfo.